Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial

BACKGROUND: The newly discovered coronavirus has turned into coronavirus disease 2019 (COVID-19) pandemic and it rages at an unprecedented rate. Considering the findings of previous studies on the use of Intravenous Immunoglobulin (IVIg) for treating severe H(1)N(1) infection and the satisfying resu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int Immunopharmacol
Autors principals: Tabarsi, Payam, Barati, Saghar, Jamaati, Hamidreza, Haseli, Sara, Marjani, Majid, Moniri, Afshin, Abtahian, Zahra, Dastan, Alireza, Yousefian, Sahar, Eskandari, Raha, Saffaei, Ali, Monjazebi, Fatemeh, Vahedi, Abdolbaset, Dastan, Farzaneh
Format: Artigo
Idioma:Inglês
Publicat: Published by Elsevier B.V. 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7665876/
https://ncbi.nlm.nih.gov/pubmed/33214093
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.intimp.2020.107205
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars